PROSTATE-SPECIFIC ANTIGEN RESPONSE TO WITHDRAWAL OF MEGESTROL-ACETATEIN A PATIENT WITH HORMONE-REFRACTORY PROSTATE-CANCER

Clinically significant responses after withdrawal of flutamide in pati ents with hormone-refractory prostate cancer (HRPC) are well documente d. Failure to recognize this syndrome of response results in potential morbidity due to salvage therapy, confusion in interpretation of dise ase state, and introduction of a possible source of error in clinical trials, In this case report, we describe a patient with HRPC whose pro state-specific antigen levels decreased substantially in response to w ithdrawal of megestrol acetate. Such a response should be considered w hen megestrol acetate is used in the treatment of HRPC.